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 Mental health nursing is a complex and radically changing discipline that must 
continuously adapt to evidence based practices, including the use of alternative options 
for the treatment of mental illness. There has recently been increased research into the 
use of hallucinogenic and sedative drugs for the treatment of mental illness. 
Hallucinogenic and sedative drugs were examined as potential treatment options for a 
variety of mental illnesses in the 1960s, although these trials were ceased by the 
government due to human safety concerns. The United States Food and Drug 
Administration (FDA) has recently approved trials to study the use of hallucinogenic 
drugs to treat mental illness, and sedative drugs, such as ketamine are currently FDA 
approved to treat major depressive disorder. This presentation will provide an overview 
of the literature regarding the history of hallucinogenic and sedative drug trials, as well as 
current research on the use of these drugs to treat mental illness. The potential impact that 
these drugs could have on mental health treatment will be discussed, as well as the 
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 Throughout the history of society, mental illnesses have been stigmatized and, in 
the past, may not have been emphasized as important to address when providing 
healthcare to individuals. In recent years, more of an emphasis has been placed on the 
treatment of mental illness and its importance in overall wellness; however, seeking 
mental health treatment may still be considered taboo in various cultures across the 
world. Individuals may fear being outcast in society due to their mental illness, and 
therefore, do not seek out the necessary treatment to live a healthy life.  
Psychiatric nurses play an important role in providing care for individuals with 
mental illness, although this area of nursing can be under-appreciated. Halter (2002) 
explores the lack of discussion about the stigmas that plague the profession of mental 
health nursing and discusses the effects of these stigmas on nursing students. Halter 
(2002) found that some students have reported the idea of psychiatric nursing as being a 
backup option, or that they had been warned by their family to not enter into this field of 
nursing. Media sources have overdramatized the role of mental health nursing and have 
contributed to some of the stigma in this area of nursing (Halter, 2002). These stereotypes 
of what are expected in a psychiatric unit or hospital are usually thought of as something 
out of a movie, such as One Flew Over Cuckoo’s Nest, Psycho, or the negative images of 
these settings from TV shows and other media outlet influences, which are readily 
available to the general public (Anderson, 2003). Great strides have been necessary in 
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recent years to reduce the stigmas and negative stereotypes of what mental healthcare and 
psychiatric nursing consists of in the eyes of the public. Psychiatric nurses can play a 
significant role in changing the idea that receiving mental healthcare is embarrassing or 
will cause societal disapproval.  
Stigmatism in the field of psychiatric nursing is not only seen with the general 
public, but also among other health care professionals. Halter (2002) described how some 
healthcare professionals assume nurses go into the psychiatric field because of their own 
psychological flaws or trauma from their childhood. These assumptions only fuel the 
stereotypes that flood this profession. Halter (2002) stated, “Psychiatric nursing’s silence 
on negative perceptions, and perhaps stigmatization by nursing students, colleagues, and 
the general public, is both noteworthy and alarming” (p. 25). It is important for not only 
the public, but also the health care community to credit the psychiatric profession with 
the recognition and value it deserves.  
  Psychiatric nursing care is much different than the care that is delivered by other 
types of nurses, such as medical surgical nurses, but is also an extremely important skill 
for nurses working in all settings. In all parts of the hospital, or any medical setting, you 
are guaranteed to run into a mental health situation. Many patients have mental health 
needs; thus, it is expected that all nurses will utilize psychiatric nursing skills during their 
career. As a psychiatric nurse, you still have the life of your patients in your hands; 
however, it is vastly different than making sure your patient stays alive from an illness 
that you can visibly see, such as hypertension or diabetes. The responsibility of the entire 
floor falls to the nursing staff as the patients are a danger to themselves or others or are 
unable to care for themselves. Psychiatric nurses then have the responsibilities of not only 
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their patients, but also the unit as a whole, which can obviously be extremely difficult 
(Thomson et al., 2019). Psychiatric nurses are also in unique a position to build rapport 
and trust with their patients and can assist with creating opportunities to help these 
patients with considering various modes of treatment options during their time of need 
(Denis-Lalonde & Estefan, 2020). 
A holistic approach must be utilized in psychiatric nursing, which allows for a 
more individualized approach to each patient’s needs. This holistic approach includes 
using the best evidence-based practice and may include the use of alternative drug 
treatments. Some of the drugs traditionally used to treat mental illness may not be as 
effective for patients as once thought (Wong, 2017). In recent years, the use of 
psychedelic and sedative drugs has been researched as a viable option for the treatment of 
a variety of mental illnesses, and some states have even legalized the use of these drugs. 
For instance, in 2020 Oregon became the first state in the nation to legalize the use of 
psilocybin, the hallucinogenic ingredient in mushrooms, as a treatment option for post-
traumatic stress disorder (PTSD), depression, and anxiety (Foden-Vencil, 2020). 
Psychiatric nurses may be in a prime position to play a role in the oversight of 





THE HISTORY OF THE USE OF PSYCHEDELIC AND SEDATIVE DRUG 
TREATMENTS FROM THE 1950’s TO THE 1960’s 
 
 
The use of psychedelic drug treatment is not new to the medical field. In the past, 
clinical trials examined the use of hallucinogenic drugs for a variety of medical 
treatments; however, due to safety and ethical concerns these trials were halted. With 
changes in clinical research trials, the use of hallucinogenic drugs has again become a 
viable treatment option, especially for individuals with mental illness; however, it is 
important to look back at the history of psychedelic drug use before exploring the current 
use of these alternative treatment options. 
 According to Wong (2017), “The idea that psychedelic drugs might be used to 
treat mental illness emerged in the 1950s, a decade or so after Swiss chemist Albert 
Hofmann first described his experiences of taking LSD” (para 4.) In the past, the drug 
LSD was used in a few unorthodox clinical trials. Most notably, in the 1960s, Doctors 
Timothy Leary and Richard Alpert, conducted the Harvard Psilocybin Project, where 
they used Psilocybin as a way to further understand human psychology as it relates to the 
environment and how psychedelics affect the human brain (Harvard University, 
Department of Psychology, 2021). The project was shut down by Harvard and both 
professors were banished from academia when it was discovered that their study did not 
follow the code of ethics. Leary and Alpert were said to have given the drug to 
undergraduate and graduate students without their consent, all while they themselves 
were using the hallucinogen (Harvard University, Department of Psychology, 2021). 
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 Dr. Sidney Cohen made waves in the 1960s discussing the use of LSD as a 
treatment for alcoholism and as a method for enhancing creativity (Novak, 1997). 
Initially, Dr. Cohen stated that LSD appeared to be safe for medical use in a supervised 
setting; however, his opinion changed in 1962 when he stated that this drug was 
dangerous. The abuse of LSD led the government to crackdown on LSD regulation. 
Before he deemed LSD dangerous, Dr. Cohen conducted three different LSD clinical 
trials to attempt to understand the drug’s effect on the human psyche. Initially Dr. Cohen 
believed that LSD had the possibility to treat some mental disorders. He mainly focused 
on treating minor personality disorders in the late 1950s. During these clinical trials, Dr. 
Cohen evaluated his patients six months after the therapy by the terms of their ability to 
find a job, sustain a relationship, or remain abstinent from alcohol, and his findings 
indicated a 73% improvement rate in these patients based on his criteria (Novak, 1997). 
Although Dr. Cohen’s research showed promise for the future use of psychedelic drugs to 
treat mental illness, LSD was being abused at the time, which eliminated any idea that it 
could be a treatment option.  
 In the 1960s, a project funded by NASA attempted to examine an unusual way to 
communicate with dolphins (Burnett, 2010). Dr. John C. Lilly injected himself and a 
dolphin named Peter with LSD in search of a new way to communicate. As would be 
expected, when NASA got word of what was happening the study was immediately shut 
down. It is important to note that this study did not go without its benefits. As a result of 
Dr. Lilly’s work, the idea that dolphins are an intelligent species was discovered and the 
Marine Life Protection Act was enacted (Burnett, 2010).  
 6 
 Another notable psychedelic drug research trial was conducted in 1957 by a 
psychiatrist named Dr. Humphry Osmond (Denis-Lalonde & Estefan, 2020). Dr. Osmond 
researched LSD and believed this drug was showing promise as a possible treatment for 
mental illness. Osmond tested the use of LSD as a way to possibly understand 
schizophrenia. He then shifted to examining LSD as a therapeutic option for alcoholism, 
which after one year demonstrated a 40-45% improvement rate in participants being 
studied; however, not long after these findings were discovered support for this type of 
research was withdrawn (Denis-Lalonde & Estefan, 2020).  
 After the cessation of the above mentioned experiments, the use of LSD, or any 
other form of psychedelics in the scientific realm became untouchable. In 1970, not long 
after these experiments, President Nixon passed the Controlled Substance Act, which 
made these once legal drugs, illegal (Philips, 2019). The idea of the therapeutic use of 
hallucinogenic drugs had become taboo and was no longer considered as viable treatment 










The use of hallucinogenic and sedative drugs has recently been reexamined as an 
option for the treatment of mental illness, since some common drug treatment options 
have been discovered as not being as effective as researchers once thought (Wong, 2017). 
For example, selective serotonin reuptake inhibitors (SSRI’s), which are drugs commonly 
used to treat depression, have only been found to be effective in 1 out of 5 people, and in 
addition, may come with undesired side effects (Wong, 2017). PTSD is a mental illness 
that can be difficult to treat and may not respond well to traditional psychiatric 
medications, and because of this psychedelics are again being researched as a potential 
treatment option for this disorder. For instance, MDMA (Ecstasy), which works by 
flooding the brain with serotonin, has recently been used in clinical trials for the 
treatment of individuals with PTSD. In these trials, MDMA allowed for 67% of 
participants to no longer experience symptoms of PTSD. These findings have led to 
increased studies into the use of hallucinogenic and sedative drug treatments for mental 
illnesses in recent years (Wong, 2017).  
The opportunity for previously illegal drugs to possibly become a treatment 
option is controversial and highly stigmatized. The lack of success in the past with 
hallucinogenic and sedative drug trials has contributed to negative views of these drugs 
as a credible treatment option. The concern for public safety as these drugs entered the 
black market made way for greater drug regulations and government intervention. Since 
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the role that these drugs play in the treatment of mental illness now have become less 
stigmatized, more research is being conducted on their potential use. Institutions, such as 
Imperial, John Hopkins, Berkley, University of California, and Icahn School of Medicine 
have all opened centers devoted to learning more about the treatment options of 
psychedelic drugs (Tullis, 2021).  
Tullis (2021) states, “psychedelic-assisted psychotherapy could provide needed 
options for debilitating mental-health disorders including PTSD, major depressive 
disorder, alcohol use disorder, anorexia nervosa and more that kill thousands every year 
in the United States, and cost billions worldwide in lost productivity” (p. 507). The proof 
behind this bold statement lies within several small studies that have been safely 
conducted with psychedelics, which have indicated a positive impact on the outcomes of 
mental illnesses. With this new information coming to light in safe clinical trials, there is 
greater possibility that some of these previously illegal drugs could now become a new 
treatment option for some difficult to treat mental health disorders. Since these alternative 
drug treatments have just recently been reexamined in research, many clinical trials have 
just ended and the results should be released soon, which will then be given to regulators 
to decide if this could be a prescription option for patients (Tullis, 2021). Of note, 
patients with schizophrenia have been excluded from current psychedelic drug trials 
because it has been found that these drugs can potentially cause long-lasting psychotic 
reactions in patients with a personal or family history of psychosis (Tullis, 2021).   
Recently, ketamine, LSD, and other psychedelic drugs have demonstrated the 
potential to be a viable treatment option for a variety of mental health disorders (Tullis, 
2021). For instance, psychedelic drug treatments have shown to be one of the most 
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effective treatment options for PTSD (Tullis, 2021). Other non-psychosis related mental 
health disorders have also had positive results from recent smaller clinical trials, which 
indicates a strong likelihood for the future use of these alternative drug option (Tullis, 
2021). Since these newer trials have been safely administered and have had reliable 
results, it is probable that soon there will be a drastic change in treatment options for 
mental health disorders.  
It is important to note that psychedelic drugs are being studied as a potential 
treatment option for non-psychiatric disorders. Psilocybin, otherwise known as 
mushrooms, has been studied as a treatment option for end of life care and smoking 
cessation (Denis-Lalonde & Estefan, 2020). End of life care is a sensitive topic and can 
be difficult for patients to talk about and for providers to treat. In a recent study 
conducted with terminally ill patients, psilocybin was shown to have a positive effect on 
the palliative care by reducing the anxiety associated with dying (Denis-Lalonde & 
Estefan, 2020). Pilot research with psilocybin for smoking cessation has been conducted 
and has shown greater success than conventional and pharmaceutical treatment options, 
with minimal side effects (Denis-Lalonde & Estefan, 2020). These research trials 
demonstrate the expansive capacity that psychedelic and sedative drug treatments may 
offer outside of psychiatry.  
Psychiatric nurses have the potential to play a crucial role in the implementation 
of psychedelic and sedative drug use as a treatment option in practice (Denis-Lalonde & 
Estefan, 2020). The literature indicates nurses have played an important role in studies 
examining psychedelic drugs, including providing therapy and other forms of support 
during clinical trials (Denis-Lalonde & Estefan, 2020). As previously mentioned, 
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psychiatric nurses are in a prime role to build a therapeutic and trusting relationship with 
patients and are well-aware of the stigmas that may accompany alternative forms of 
treatment, such as the ones discussed in this paper. Psychiatric nurses can use the safety 
of the therapeutic relationship to examine any concerns patients may have about using 
these drugs and can assist the patient with deciding if this is a viable treatment option for 
them. 
There is a long and difficult path in front of the psychedelic and sedative drug 
treatment movement, due to the fact that there are many obstacles, such as stigma, to 
overcome; however, this has not deterred scientists from researching the use of these 
drugs in current and future practice. Many scientists feel confident that we are on a verge 
of a major breakthrough for how we treat mental illness with these alternative forms of 
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